DROR vs NVST vs HSIC Stock Comparison

Dror Ortho-Design, Envista Holdings and Henry Schein Prices as of Oct 23, 2026 Peers: Industry group
1 more company in this comparison (PDEX) Create a free account to keep reading and compare up to 10 companies.
HSIC Henry Schein Inc
$84.51 -2.2% 1M +32.4% 1Y
Market cap
$9.56B
P/E
23.7x
Revenue (TTM)
$13.60B
Div. yield
–
Drug Distribution Healthcare
7 wins

Head to Head

11 decided of 12

Henry Schein leads on 7 of the 12 questions below (Henry Schein 7, Envista Holdings 3, Dror Ortho-Design 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDRORNVSTHSICLeader
Larger companyMarket capitalisation $9.77M $3.82B $9.56B HSIC
Cheaper on earningsLower P/E, profitable companies only -4.0x 40.2x 23.7x HSIC
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 15.8x 14.7x HSIC
Faster revenue growthRevenue growth, trailing twelve months — +11.9% +6.5% NVST
More profitableNet margin, trailing twelve months — 3.3% 3.0% NVST
Better return on capitalReturn on invested capital — 2.5% 7.1% HSIC
Less leveragedLower net debt / EBITDA -1.3x 0.8x 3.3x DROR
Higher dividend yieldTrailing dividend yield — 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months 0.0% +16.1% +32.4% HSIC
Better 5-year returnAnnualised price return, 5 years -35.6%/yr -8.9%/yr +2.6%/yr HSIC
Less volatileAnnualised volatility, 1 year 320.7% 37.9% 25.7% HSIC
Higher overall scoreMean of the five percentile scores vs peers 26/100 74/100 56/100 NVST

Percentile Scorecard

DRORNVSTHSIC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDRORNVSTHSIC
Valuation 16 #192 of 228 97 #7 of 228 38 #16 of 25
Growth 62 #84 of 221 49 #113 of 221 39 #15 of 24
Profitability – 74 #55 of 208 83 #5 of 24
Financial Health 1 #237 of 239 51 #117 of 239 20 #21 of 26
Shareholder Returns – 96 #6 of 137 100 #1 of 16
Overall 26 74 56
  • DROR ranked among 248 companies in Medical Devices and Diagnostics
  • NVST ranked among 248 companies in Medical Devices and Diagnostics
  • HSIC ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDRORNVSTHSICSPY
1 month 0.0%-1.3%-2.2% -0.8%
3 months 0.0%-11.2%-0.1% +3.5%
6 months 0.0%-11.7%+9.5% +7.0%
Year to date 0.0%+8.9%+11.8% +12.2%
1 year 0.0%+16.1%+32.4% +13.0%
3 years -50.0%+0.5%+27.3% +86.3%
3 years, per year -20.6%+0.2%+8.4% +23.1%
5 years -88.9%-37.3%+13.9% +68.6%
5 years, per year -35.6%-8.9%+2.6% +11.0%
10 years ——+44.7% +258.0%
10 years, per year ——+3.8% +13.6%

Risk

MeasureDRORNVSTHSICSPY
Volatility, 1Y 320.7%37.9%25.7% 12.7%
Downside volatility, 1Y 1,199.8%34.7%24.1% 12.7%
Beta vs S&P 500, 1Y 0.131.150.46 1.00
Return / volatility, 1Y 0.000.431.26 1.02
Max drawdown, 5Y -92.3%-71.0%-32.7% -25.4%
From 52-week high -66.7%-21.9%-7.0% -1.8%
52-week high $0.03$30.26$90.86 $779.14
52-week low $0.01$18.95$62.32 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDRORNVSTHSIC
P/E now vs peer median -4.0xmedian 30.6x 40.3xmedian 30.6x 23.8xmedian 24.3x
P/S now vs peer median —median 3.0x 1.3xmedian 3.0x 0.7xmedian 0.3x
EV/EBITDA now vs peer median -8.4xmedian 17.5x 10.6xmedian 17.5x 12.7xmedian 13.5x
P/FCF now vs peer median -5.5xmedian 23.3x 15.3xmedian 23.3x 16.6xmedian 15.6x
P/B now vs peer median -2.5xmedian 2.4x 1.2xmedian 2.4x 2.5xmedian 2.5x
PEG now vs peer median -0.12median 0.87 -1.81median 0.87 49.82median 1.33

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDRORNVSTHSIC
Revenue – $2.86B $13.60B
Gross profit – $1.58B $4.26B
Operating income -$1.91M $273.60M $680.00M
Net income -$2.47M $95.00M $426.00M
Free cash flow -$1.78M $248.10M $569.00M
R&D $521.41K $120.80M –
EPS (diluted) $0.00 $0.58 $3.52
Cash & equivalents $93.56K $1.13B –
Total debt $5.57M $1.44B $3.46B
Shares (diluted) 977.00M 164.10M 114.39M
Enterprise value $9.18M -$734.78M $9.40B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDRORNVSTHSIC
P/E -4.0x 40.3x 23.8x
P/FCF -5.5x 15.3x 16.6x
P/Operating cash flow -5.5x 12.5x 13.5x
P/S – 1.3x 0.7x
P/B -2.5x 1.2x 2.5x
P/Tangible book -2.5x 1.5x 3.3x
EV/EBITDA -8.4x 10.6x 12.7x
EV/EBIT -6.1x 15.0x 18.8x
EV/Revenue – 1.4x 0.9x
EV/FCF -6.5x 16.6x 22.4x
EV/Operating cash flow -6.5x 13.6x 18.2x
PEG (3Y EPS CAGR) -0.12 -1.81 49.82

Growth

14 metrics
MetricDRORNVSTHSIC
Revenue growth (1Y) – 11.9% 6.5%
Revenue CAGR (3Y) – 3.4% 2.6%
Gross profit growth (1Y) – 13.1% 6.4%
Gross profit CAGR (3Y) – 2.3% 3.4%
Operating income growth (1Y) 49.0% 79.6% 6.6%
Operating income CAGR (3Y) -5.3% -4.4% 1.1%
Net income growth (1Y) 42.4% 76.6% 6.0%
Net income CAGR (3Y) -15.2% -24.0% -4.5%
EPS growth (1Y) 43.6% 82.8% 11.1%
EPS CAGR (3Y) 31.8% -22.2% 0.5%
Operating cash flow growth (1Y) 20.4% 3.6% 36.7%
Operating cash flow CAGR (3Y) 10.2% 8.8% 2.3%
Free cash flow growth (1Y) 20.4% -3.8% 50.1%
Free cash flow CAGR (3Y) 10.2% 15.8% 2.3%

Profitability

14 metrics
MetricDRORNVSTHSIC
Gross margin – 55.2% 31.3%
EBITDA margin – 13.6% 7.4%
Operating margin – 9.6% 5.0%
Pretax margin – 8.2% 4.1%
Net margin – 3.3% 3.0%
FCF margin – 8.7% 4.2%
Operating cash flow margin – 10.6% 5.1%
Return on equity – 3.1% 11.0%
Return on assets -798.5% 1.7% 3.8%
Return on invested capital – 2.5% 7.1%
Return on capital employed – 5.7% 8.7%
Asset turnover – 0.5x 1.2x
Cash conversion (OCF / net income) 0.7x 3.2x 1.6x
Stock comp / revenue – 1.4% 0.3%

Financial Health

11 metrics
MetricDRORNVSTHSIC
Debt / assets 512.4% 25.7% 30.4%
Debt / equity -0.5x 0.5x 0.9x
Net debt / EBITDA -1.3x 0.8x 3.3x
Debt / FCF -1.1x 5.8x 6.1x
Liabilities / assets 1,177% 45.0% 66.5%
Equity / assets -1,077% 55.0% 33.5%
Interest coverage – – 4.3x
Current ratio 0.1x 2.4x 1.3x
Quick ratio 0.0x 1.9x 0.6x
Cash ratio 0.0x 1.4x 0.0x
Altman Z-score – 1.73 2.65

Shareholder Returns

7 metrics
MetricDRORNVSTHSIC
Dividend yield – – –
Net buyback yield – 4.3% 7.7%
Shareholder yield – 4.3% 7.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDRORNVSTHSIC
Forward P/E – 15.8xFY2026 14.7xFY2026
EPS, next fiscal year – $1.50FY2026 $5.75FY2026
EPS growth, next FY – +26.1%FY2026 +15.7%FY2026
EPS growth, the year after – +16.7% +8.2%
Revenue, next fiscal year – $2.99BFY2026 $13.38BFY2026
Revenue growth, next FY – +9.8%FY2026 +1.5%FY2026
Revenue growth, the year after – +2.6% +4.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDRORNVSTHSIC
Held by institutions – 100.0% 100.0%
Institutions holding – 382 564
Change in shares held, QoQ – +6.4% +2.1%
Institutions buying – 200 245
Institutions selling – 129 216
Buyers to sellers – 1.55 1.13

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DRORNVSTHSIC
DROR 1.00 0.00 0.05
NVST 0.00 1.00 0.58
HSIC 0.05 0.58 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DROR, NVST and HSIC?

Henry Schein (HSIC) is the largest by market capitalisation: Dror Ortho-Design (DROR) $9.77M, Envista Holdings (NVST) $3.82B, Henry Schein (HSIC) $9.56B.

Which stock is cheaper, DROR, NVST and HSIC?

Henry Schein (HSIC) trades on the lowest price-to-earnings ratio (Dror Ortho-Design (DROR) -4.0x, Envista Holdings (NVST) 40.2x, Henry Schein (HSIC) 23.7x). On next year's consensus earnings, Henry Schein (HSIC) is cheapest (Envista Holdings (NVST) 15.8x, Henry Schein (HSIC) 14.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Envista Holdings (NVST) grew revenue fastest over the trailing twelve months: Envista Holdings (NVST) +11.9%, Henry Schein (HSIC) +6.5%.

Which company is more profitable?

Envista Holdings (NVST) has the highest net margin (Envista Holdings (NVST) 3.3%, Henry Schein (HSIC) 3.0%). On return on invested capital, Henry Schein (HSIC) leads (Envista Holdings (NVST) 2.5%, Henry Schein (HSIC) 7.1%).

Which stock has performed better?

Over the past year Henry Schein (HSIC) returned the most: Dror Ortho-Design (DROR) 0.0%, Envista Holdings (NVST) +16.1%, Henry Schein (HSIC) +32.4%. Over five years, Henry Schein (HSIC) compounded fastest (Dror Ortho-Design (DROR) -35.6%/yr, Envista Holdings (NVST) -8.9%/yr, Henry Schein (HSIC) +2.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Henry Schein (HSIC) has been the steadiest (Dror Ortho-Design (DROR) 320.7%, Envista Holdings (NVST) 37.9%, Henry Schein (HSIC) 25.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DROR, NVST and HSIC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Henry Schein (HSIC) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.